R$ 1.5 billion invested in scientific projects and to enlarge our technological area
For the next four years, the Ministry of Health will rise fourfold the amount invested in the research and development areas to innovate the sector. Recently, it was presented an investment plan with an amount of R$ 1.5 billion, R$ 350 million per year. Those resources will be applied on strategic actions defined according to the set of major themes aligning a national research with the country’s needs.
“When the Ministry of Health has as goal the quality access to every Brazilian citizen, it is fundamental to strengthen initiatives that focuse the research, development and innovation in health”, said the Minister of Health, Alexandre Padilha. In the past four years, the Ministry of Health has applied R$ 400 million – equivalent to 53% of the whole resources invested in the sector in Brazil.
Two new measures are promising to accelerate both the process of approval of tests with new drugs involving human beings in the country and the publication of articles written by Brazilian researchers. Two platforms will gather research projects and clinical experiments in on-line digital environments: “Plataforma Brasil” and the Brazilian Registration of Clinical Experiments (Rebec).
Also, it is being launched a course to the rational use of medications which will qualify health professionals in assisting patients. At the same time, a research performed in 35 thousand dwells in the country will survey how Brazilian people has access to products, follows the treatment, uses and removes medications as well. It will begin this year and it must be concluded in 2013.
Furthermore, the Minister of Health was recently in Cube to sign a mutual cooperation agreement involving research, development and production of medications and other products to the health. Those partnerships involve 58 research and development projects with 12 new medications related, mainly to the therapy and diagnosis of different types of cancer, prevention of amputations as a consequence of diabetes added to vaccines. Brazil and Cube has also settled a cooperation in clinical research in onchological areas and for the articulation of unique clinical experiment platforms in Latin America – certified by the World Health Organization.
Among the major agreements, it is the transfer of technology from Cube to Brazil to produce a drug that promises to reduce in more than 50% amputations in diabetic patients: Heberprot-P indicated to treat a problem known as the “ulcer of the diabetic foot”. Another important point is the collaboration for the development of monoclonal antibodies, capable of recognizing cancer cells, thus sparing healthy cells and resulting in less toxic effects than the traditional chemotherapy. The majority of medications is composed by monoclonal antibodies which are in the frontier in the worldwide biotechnology.
Seven innovating onchological drugs researched and developed in Cube are among the priorities for the collaboration with Brazil, and that is the more important area in the technological collaboration between both countries.
Diabetes is among the main causes of death among the Brazilian people, being responsible by more than 57 thousand deaths all over the country. Besides of increasing the assistance to diabetic patients through the SUS using the drug Heberprot-P, the co-operation agreement to produce such medication will have impact on the Brazilian Economy by allowing that the product be exported to other countries.
(Source: Agência Saúde – Ascom/MS)
Valorization of the Brazilian science abroad
As a reflection of the higher visibility attained by Sciences in Brazil, the new international insertion of the National Scientific Communication was theme of the II Seminary to Assess the Development in the Brazilian Publications. First published by the Journal Citation Reports (JCR), the present version of that document presents results that show an increasing participation in scientific publications edited in Brazil in the international scenery. In 2010, 103 publications from different areas of knowledge were indexed in the JCR, representing a 43% increase in relation to 2009, including the JCR Science and JCR Social Sciences compilations.
The majority of the Brazilian publications listed in the JCR by the Scientific Electronic Library Online (SciELO) – an electronic library of scientific publications – has kept or improved its performance in terms of quotations received. As to Latin American and other emerging countries including China and India, the relative performance of those publications presented an exceptional advancement. During the seminary, scientific communication and scientometry experts debated the features and consequences that appear in such context in which the amount of quotations is an important assessment factor for scientific magazines, influencing publications in several areas.
Brazilian publications are in accordance to the Thomson Reuters’ policy, company responsible by the JCR, and this has been a benefit to the international repositioning of the Science developed in Brazil particularly national publications. From them, 11 kept a higher than 1 Impact Factor in 2010, and this represents an advancement to the visibility of the scientific research of the country.
(Gerência de Comunicação da FAPESP / Assessoria de Comunicação - Fernando Cunha / Samuel Antenor (11) 3838-4151 / 3838-4381 / fapesp-imprensa@fapesp.br)
Ascension of the scientific production in the country
The magazine Clinics is a scientific publication of Hospital das Clinicas of the Medical College of São Paulo, and it is an excellent example of the Brazilian scientific evolution and it brought in its September issue 20 original articles, a review of article, three communications and three case reports.
“The Brazilian scientific production is in a moment of international ascension and recognition. The magazine Clinics has increased its influence in the world of Medical Sciences and it has become an important showcase for researches”, said Dr. Maurício Rocha e Silva, editor.
Among the studies reported, there is a paper on allergic rhinitis; the relationship between exposition to tobacco in teenager mothers along the prenatal period and its consequences in newborns, and studies on cholesterol in elder people and teenagers.
For Dr Mauricio Rocha e Silva, the articles published in Clinics magazine is attaining international importance because they are being published in English and in an online version indexed on the main database and medical libraries across the world.
An Exchange straitens partnership in clinical and lab researches
Hospital de Câncer in the city of Barretos (cty in the countryside of the state of São Paulo) is the new co- institution of the MD Anderson Cancer Center Institute (EUA), the biggest and most important Oncology institution in the world.
An excellence in Oncology, the hospital records 3 thousand attendances/Day, totally focused on patients from the Unified Health System (SUS). It shelters people all over Brazil with professionalism and humanization, and this is the big differential of that institution. The hospital closed 2010 with 484,269 attendances performed to 50,865 patients from 1372 cities of all the Country’s 27 states - a record coverage. It gathers 250 physicians and more than 2.5 thousand employees, and it keeps 13 free lodgings to patients and caretakers of those patients in an amount of 650 vacancies.
The agreement signed by Henrique Prata, manager of that hospital and Raymond DuBois, Executive President for MD Anderson will allow the Exchange of professionals and researchers between both institutions besides of straitening the partnership in clinical and lab researches.
It is the first time a hospital from the government network receives such title in Brazil. "This agreement will allow that institutions learn from each other always in benefit of patients", said Edmundo Mauad, Scientific Director for the HCâncer Barretos.
Raymond DuBois explained that Hospital do Câncer de Barretos has been performing amazing progresses in its efforts to offer quality attendance to its patients, including important papers in the prevention area."Such partnership will help us to understand the challenges faced by the destitute population in Brazil, also allowing us not only to learn with its experiences and incorporating such knowledge at MD Anderson, but also granting a support to improve even more the attendance for patients", he concluded.
MD Anderson Cancer Center of the Texas University has marked its 70th anniversary in 2011, and it is one of the most respectful centers of the world exclusively dedicated to attend patients with cancer, research, education and prevention.
Another partnership involving six Brazilian hospitals and famous worldwide entities from approximately 25 counties shall define a worldwide protocol as to the type of optimum childbirth in the pregnancy of twins. The Hospital of the Medical College of the Medical Scholl in Jundiaí became one of the sites the Toronto, Canada has chosen to participate in that project.
The project developed by that hospital has started in February, 2009 and it allowed that pregnant women of twins to be sorted to define if the patient would be allowed to be included in the program, and it is in its final phase, and around 26 patients were randomized. For the feasibility of the Twin Pregnancy Project, it was created a prenatal ambulatory, and pregnant women from the city of Jundiaí (SP) and region were sent to the hospital to be followed along their pregnancy, the delivery and in the post birth. The twin newborns are also being monitored until the age of two years old.
The frequency of twin pregnancy in the world is of one each 80 deliveries. Today, the best alternative for deliveries of twins is unknown; the majority is born from a caesarian surgery, but that paper shall confirm or change such preference.
In order to reach to a final conclusion, it was necessary 2800 randomized twins pregnant women all over the world.
(foto em arquivo HCâncer Barretos)
Legenda:
Henrique Duarte Prata (General Director for the Hospital do Câncer de Barretos, Dra. Scylla Duarte Prata (President of the Pio XII Foundaton), Raymond N. Dubois (Executive Vice-President of the Texas University - MD Anderson Cancer Center)
Não traduzir:
Assessoria HC Barretos:
Orlando
Aguiar de Oliveira
Porta-Voz Comunicação Estratégica
(11) 3871-3666 / (11) 9733-6263
orlando.oliveira@portavoz.com.br
Assessoria de Imprensa do HU de Jundiaí
Marília Porcari Gerciano /(11) 4527-5734/ 7644-1813
22/09/2011 - BRASIL E CUBA
Agreements which will allow new medications to the SUS
The partnership represents a landmark in the technological cooperation between both countries Who are leaders in the health research and technology in Latin America. The cooperation involves 58 projects and high-tech 12 products to treat different diseases such as cancer and diabetes
By Bárbara Semerene, Health Agency
Press Atendance
3315-3580/2918